It is disclosed a therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders, wherein the therapeutic composition comprises at least one active agent being selected from the following active agent groups a) to e): a) complement factor 3-targeting inhibitor of complement activation cascade b) carboxypeptidase B enzyme c) complement factor 5a receptor-targeting inhibitor of complement activation cascade d) endothelin A receptor-targeting inhibitor of extravasation e) bone morphogenic protein.

It is further disclosed a method of treating COVID-19 and other cytokine storm associated disorders, wherein said method comprises administering an effective amount of at least one active agent being selected from the above mentioned active agent groups a) to e).

A process for solubilization and refolding of precursor insulin or insulin analogs from inclusion body isolates for use in the production of insulin or insulin analog is described.

The present disclosure relates to a comprehensive model for expression of recombinant peptides by Pichia pastoris. The model uses an easily controllable variable called critical nutrient ratio for obtaining a right balance between product synthesis and it's degradation during the fermentation process. The extra cellular concentration of precursor could be increased by about 10 folds and the degradation constants could be reduced by about 10-20 folds for intracellular and extracellular cases respectively by controlling critical nutrient ratio and addition of soya flour hydrolysate and EDTA.

The method for preparation of a recombinant protein from a precursor, preferably mammalian insulins, including human insulins and their analogues, characterised in that a protease is used which hydrolyses one or more peptide bonds in this protein, wherein the protease disrupts the peptide bond from the C-end side of a basic amino acid, when the amino acid is the second one after other basic or neutral amino acid, and such an order enables specific recognition of both amino acids by the protease. The invention is applicable in biotechnology and pharmaceutical industry.

This invention describes a new analytical method to determine the quantity and distribution of fucose per Fc within an antibody preparation.

This disclosure is based, in part, on the unexpected discovery that a piRNA-based construct is able to silence genes that are essential for transmission and/or infection of pathogens. The disclosed constructs and methods of use thereof capitalize on the role piRNAs play in transcriptional silencing and general immunity and enable development of transgenic approaches to inhibit transmission of human and crop diseases.